Table 4.
Oxidative stress in patients with rheumatoid arthritis using adalimumab or etanercept.
| Parameters | Etanercept n = 26 |
Adalimumab n = 13 |
p |
|---|---|---|---|
| CL-LOOH (cpm) | 164.02 (145.51–187.05) | 168.06 (162.71–197.90) | NS |
| AOPP (μmol/L of chloramines-T equivalents) | 127.44 (108.75–187.05) | 167.80 (122.90–228.73) | 0.071 |
| TRAP (μM Trolox/mg UA) | 157.27 (15.84–183.51) | 159.70 (148.83–175.58) | NS |
| OSI | 1.10 (0.77–1.31) | 0.86 (0.74–1.37) | NS |
Mann-Whitney test. Data are expressed as median (25–75%). CL-LOOH, tert-butyl hydroperoxide-initiated chemiluminescence; AOPP, advanced oxidation protein product; TRAP, total radical-trapping antioxidant parameter; OSI, oxidative stress index; and NS, not significant.